News Column

Findings from University Nova of Lisboa Broaden Understanding of Pharmaceutical Research (Synthesis and evaluation of sodium deoxycholate sulfate as...

August 8, 2014



Findings from University Nova of Lisboa Broaden Understanding of Pharmaceutical Research (Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B ...)

By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Drugs and Therapies. According to news reporting from Lisbon, Portugal, by NewsRx journalists, research stated, "Amphotericin B (AmB) is still used as the gold standard for therapy against invasive fungal diseases. However, the use of AmB through oral administration is restricted due to its low solubility and stability in aqueous solution, which is the cause for its poor bioavailability and highly varying absorption."

The news correspondents obtained a quote from the research from the University Nova of Lisboa, "Therefore, an attempt has been made to enhance the solubility and stability of AmB to evaluate its bioactivity and safety for use as an inhaler by using a new excipient sodium deoxycholate sulfate (SDS) with aim of using it as a drug carrier for AmB. Therefore, SDS was formulated together with AmB as a dry powder by lyophilization. The dry powder was reconstituted in distilled water and evaluated its physicochemical properties such as zeta potential, particle size and pH to compare its solubility and stability of the formulations with a SDC-AmB (i.e., known as Fungizone ). In vitro toxicity studies were carried out with red blood cells (RBC) and respiratory cell lines. Bioactivity was determined by a micro-dilution method against Candida albicans and Cryptococcus neoformans. We found that SDS-AmB had a zeta potential (-45.53 mV), which was higher than of Fungizone ; and produced a stable particle size in solution (73.8 nm). The particle size distributions of both formulations were expressed as their mass median aerodynamic diameters (MMAD; 1.70 and 1.74 mu m), their fine particle fractions (FPF; 70 and 80%) and geometric standard deviations (GSD; 2.3 and 2.0), respectively. These values indicated that the sizes were appropriate for use in an inhaler. Pure AmB was found to hemolyse RBC and was very toxic to alveolar macrophage cells, as their viability rapidly declined from 93 to 56% when the AmB concentration increased from 1 to 8 mu g/mL. The SDS-AmB formulation had a significantly reduced toxicity compared to AmB."

According to the news reporters, the research concluded: "The results clearly indicated that the SDS-lipid based nanoparticles had the potential to be used as an alternative option to Fungizone for an AmB formulation for inhalation."

For more information on this research see: Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation. International Journal of Pharmaceutics, 2014;471(1-2):430-438. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)

Our news journalists report that additional information may be obtained by contacting K.N. Gangadhar, Univ Nova Lisboa, Inst Chem & Biol Technol, Lisbon, Portugal. Additional authors for this research include K. Adhikari and T. Srichana (see also Drugs and Therapies).

Keywords for this news article include: Lisbon, Europe, Portugal, Drugs and Therapies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Drug Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters